Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapeutic approaches in multiple sclerosis.

Luciano Adorini1

  • 1BioXell, Via Olgettina 58, I-20132 Milan, Italy. Luciano.Adorini@bioxell.com

Journal of the Neurological Sciences
|July 21, 2004
PubMed
Summary

Immunotherapy for multiple sclerosis (MS) targets T cell modulation. Strategies include antigen recognition, cytokine neutralization, and regulatory cell induction for improved treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off-Target Effects.

ChemMedChem·2026
Same author

Farnesoid X Receptor Agonist INT-787 Inhibits Hepatic Mitochondrial Dysfunction in a Diet-Induced ob/ob Mouse Model of MASH.

International journal of molecular sciences·2025
Same author

Farnesoid X receptor inhibits proinflammatory cytokine-induced epithelial necroptosis in vitro: implications for preservation of intestinal barrier function.

American journal of physiology. Gastrointestinal and liver physiology·2025
Same author

Aberrant basement membrane production by HSCs in MASLD is attenuated by the bile acid analog INT-767.

Hepatology communications·2024
Same author

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.

PloS one·2024
Same author

FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.

Liver international : official journal of the International Association for the Study of the Liver·2023

Area of Science:

  • Immunology
  • Neuroimmunology
  • Pharmacology

Background:

  • Understanding T cell activation, inactivation, and modulation is crucial for developing multiple sclerosis (MS) immunotherapies.
  • Current MS immunotherapies aim to selectively intervene in key immune pathways.
  • Despite successes like interferon-beta and glatiramer acetate, many approaches have faced challenges.

Purpose of the Study:

  • To review current and emerging immunotherapeutic strategies for multiple sclerosis (MS).
  • To highlight key targets for selective immunointervention in MS.
  • To discuss the potential of novel approaches in MS treatment.

Main Methods:

  • Review of established and experimental immunotherapeutic strategies for MS.
  • Analysis of targets including antigen recognition, costimulation blockade, and cytokine modulation.
  • Exploration of novel avenues like chemokine receptor antagonists and dendritic cell targeting.

Main Results:

  • Several immunotherapeutic strategies have been developed, targeting various aspects of T cell-mediated autoimmunity in MS.
  • Interferon-beta and glatiramer acetate represent successful, albeit non-specific, immunotherapies.
  • Promising new strategies focus on selective targeting of T helper cell subsets and induction of regulatory T cells.

Conclusions:

  • Future MS immunotherapy may involve combined antigen- and cytokine-based approaches to target autoreactive T cells.
  • Novel strategies, including chemokine receptor antagonists and dendritic cell modulation, show significant promise.
  • Continued research into selective immunointervention is essential for advancing MS treatment.

Related Experiment Videos